NCT05039086

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - PDE5

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- PDE5

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 13,021 (actual)
• Sponsor: Brigham and Women's Hospital · Academic / Other
• Sex: All
• Age: 65 Years
• Healthy volunteers: —

Summary

This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.

Detailed description

This is a non-randomized, non-interventional study that is part of the DREAM Study of Brigham and Women's Hospital. DREAM is led by Dr. Madhav Thambisetty, MD, PhD, Chief of the Clinical and Translational Neuroscience Section, Laboratory of Behavioral Neuroscience, National Institute on Aging (NIA) intramural research program. This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication using healthcare claims data.

Conditions

• Pulmonary Arterial Hypertension

Interventions

Type	Name	Description
DRUG	PDE5 inhibitor	PDE5 inhibitors (sildenafil, tadalafil) claim is used as the exposure group.
DRUG	Endothelin Receptor Antagonists	Endothelin receptor antagonists (bosentan, ambrisentan, macitentan) claim is used as the reference group.

Timeline

• Start date: 2021-09-01
• Primary completion: 2021-09-30
• Completion: 2022-10-04
• First posted: 2021-09-09
• Last updated: 2025-08-06
• Results posted: 2024-02-20

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study